NCT05393063View on ClinicalTrials.gov

A Study to Evaluate the Efficacy and Safety of AK127 in Patients With Advanced Solid Tumors

PHASE1UnknownINTERVENTIONAL

Enrollment

36

Participants

Timeline

Start Date

June 30, 2022

Primary Completion Date

June 30, 2023

Study Completion Date

June 30, 2024

Conditions

Advanced Solid Tumors

Interventions

DRUG

AK127

Subjects will receive AK127 by intravenous administration（administered on Day 1 of each cycle, Q3W）

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Akeso

INDUSTRY

NCT05393063 - A Study to Evaluate the Efficacy and Safety of AK127 in Patients With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter